GLEN ALLEN, Va.--(BUSINESS WIRE)--Osteologix, Inc. (OTCBB:OLGX) today announced that is has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/269,289 titled "Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions" reporting allowance of claims covering the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the Company's lead osteoporosis drug candidate. The Company expects the patent will issue in the second half of 2009; the patent's 20-year term would expire in 2024. The company has a number of other pending patent applications covering various aspects of the NB S101 drug program including composition, manufacturing and method of use patent applications.
